‘Non-Medical Switching’ Claim Riles Europe’s Biosimilars Industry
Executive Summary
Two patient advocacy groups have said that a number of issues surrounding biosimilar switching, patient consent and traceability remain to be addressed in Europe, despite growing support for biosimilar use from physician bodies and clinical studies. But the European biosimilars industry has dismissed these concerns, saying that biosimilar medicines will significantly improve access to biologics patients while contributing to the sustainability of pharmaceutical budgets.
You may also be interested in...
Industry Bodies Warn Against Switching Among Biosimilars
EFPIA, the EBE and the IFPMA have issued a joint position paper in which they address a number of issues relating to biosimilars, including a caution against switching patients from one biosimilar of a reference drug to another.
Industry Bodies Warn Against Switching Among Biosimilars
EFPIA, the EBE and the IFPMA have issued a joint position paper in which they address a number of issues relating to biosimilars, including a caution against switching patients from one biosimilar of a reference drug to another.
Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.